Leqvio vs Lisinopril
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Leqvio | US Lisinopril | |
|---|---|---|
| Generic name | inclisiran | lisinopril |
| Drug class | siRNA PCSK9-Lowering Therapy | ACE Inhibitor |
| Treats | High cholesterol, cardiovascular disease | High blood pressure, heart failure |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Novartis | Various (generic) |
| Year approved | 2021 | 1987 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $90M | $1M |
| Common side effects | Injection site reactions, Joint pain, Urinary tract infection, Shortness of breath | Dry cough, Dizziness, High potassium, Headache |
Lisinopril
Frequently asked questions
Is Leqvio or Lisinopril better?
Neither is universally "better." Leqvio (inclisiran) and Lisinopril (lisinopril) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Leqvio and Lisinopril?
Leqvio is a siRNA PCSK9-Lowering Therapy made by Novartis, while Lisinopril is a ACE Inhibitor made by Various (generic). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Leqvio has the larger estimated TV advertising budget of the two.